GLP-1 reconstitution and titration: the real dose risk

Key takeaways

• Reconstitution has two math layers: powder to concentration (simple multiplication), then dose to draw volume to syringe units (the chain that goes wrong). Approved products drop the second layer by arriving at a fixed, known concentration .
• On a U-100 insulin syringe each unit marking is 0.01 mL, not one milligram. Converting milligrams to units or mL wrong is the error the FDA blames for compounded-semaglutide overdoses of five to ten times, and in some reports up to twenty times, the intended dose, with hospitalizations .
• The FDA says compounded salt forms (semaglutide sodium, semaglutide acetate) are different active ingredients from approved semaglutide and their equivalence is not established, so a milligram-for-milligram conversion off a labeled product is not safe to assume .
• Both approved injectable ladders step every four weeks: semaglutide 0.25 to 2.4 mg over 16 weeks, tirzepatide 2.5 to 15 mg over a 20-week escalation . GI side effects cluster during that climb, not at the top dose, so how fast you escalate matters as much as the dose .
• Wegovy's missed-dose rule: if the next dose is more than 48 hours away, take the missed one, otherwise skip; miss two weeks in a row and restart escalation lower . Zepbound and Mounjaro: take within 96 hours, and keep at least 72 hours between any two doses .

Skip to:

• What the arithmetic actually is, in two layers
• U-100 vs. U-50 syringes, and why the marking system is a trap
• Rounding error scales with concentration, and stacks over the ladder
• Bacteriostatic water volume, and what the label actually specifies
• What a defensible titration plan looks like, drawing from published trial design
• Where the dose calculator gets the answer right but misses the risk
• Missed doses and mid-titration interruptions
• What actually protects you: known inputs and a planned ladder

What the arithmetic actually is, in two layers

Reconstitution math has two distinct layers. The first turns a vial of lyophilized peptide and a measured volume of bacteriostatic water into a concentration. A vial holding 5 mg of semaglutide reconstituted with 2 mL of bacteriostatic water comes out at 2.5 mg per mL, or 2500 mcg per mL. That step is multiplication and division, and a calculator handles it cleanly.

The second layer is where it goes wrong. It turns a planned weekly dose in milligrams into a draw volume in milliliters, then into unit markings on whatever syringe you have, then leaves you to read how the barrel rounds the draw. The dose you actually inject is the product of all three steps. A GLP-1 conversion calculator runs that milligram-to-units chain so the rounding shows up on screen. Approved GLP-1 products skip the chain entirely by arriving at a fixed, known concentration, whether a calibrated pen or a fixed-strength vial . Compounded vials hand the chain back to you.

U-100 vs. U-50 syringes, and why the marking system is a trap

Insulin syringes are calibrated in units. A U-100 syringe is built so 100 units fill 1 mL; a U-50 syringe so 50 units fill 0.5 mL. Those unit numbers only stand for a fixed amount of drug when the drug is U-100 insulin (100 IU per mL). For anything else, a unit is just a volume marking, and the conversion is on you.

GLP-1 peptides are dosed in milligrams. Insulin is dosed in international units, and the U-100 syringe was built for insulin, which is where the trouble starts. Draw semaglutide from a 2.5 mg per mL vial up to the '20' mark on a U-100 syringe and you have drawn 0.20 mL. At that concentration 0.20 mL is 0.5 mg. It is not 20 mg, and it is not 20 mcg. The number is right only if you know the U-100 mark is a volume (mL divided by 100), not a count of milligrams.

• U-100 syringe: 1 marking equals 0.01 mL. Common sizes are 0.3, 0.5, and 1 mL, holding 30, 50, and 100 unit markings respectively.
• U-50 syringe: 1 marking still equals 0.01 mL on the 0.5 mL size, but the barrel is labeled 0 to 50 instead of 0 to 100. The fluid per marking is the same; only the label changes.
• U-40 syringes exist for veterinary insulin and should never be used for human GLP-1 work; the unit marking there represents a different fluid volume per increment.

The FDA alert names this milligram-versus-units confusion as a repeated cause of compounded-GLP-1 overdoses . It is the failure mode to design against first.

Rounding error scales with concentration, and stacks over the ladder

A U-100 syringe with 100 markings on a 1 mL barrel resolves to 0.01 mL per marking, and in practice the eye reads to about half a marking, 0.005 mL. At 2.5 mg per mL that half-marking is about 12.5 mcg, small next to a typical weekly GLP-1 dose. Reconstitute the same 5 mg vial with 1 mL of bacteriostatic water instead of 2 and you are at 5 mg per mL, where the same half-marking is 25 mcg. The rounding error scales straight up with concentration.

The stacking effect comes from the titration ladder. Semaglutide climbs 0.25, 0.5, 1.0, 1.7, then 2.4 mg, four weeks per step ; tirzepatide runs 2.5 mg up to 15 mg in 2.5 mg steps across a 20-week escalation . Self-titrate from one high-concentration vial across all of that and the marking resolution holds constant in volume but shrinks as a fraction of each larger draw, so the same slip of the plunger is a different-sized dose error at every step.

The fix is concentration-aware. A lower concentration shrinks the rounding error relative to the dose, but it also pushes the draw volume past a 0.5 or 1 mL syringe at the top of the ladder. A workable reconstitution picks a concentration that keeps every planned step between a 0.10 and 0.40 mL draw, where rounding sits between roughly 1 and 5 percent of the dose. Outside that band the error grows at both ends: too little volume to read cleanly at high concentration, too much volume to fit at low.

Bacteriostatic water volume, and what the label actually specifies

Bacteriostatic water for injection is sterile water with 0.9 percent (9 mg per mL) benzyl alcohol added as a preservative. It is meant for multiple-dose vials drawn over several administrations, because the preservative limits microbial growth between needle entries . Sterile water for injection carries no preservative and is intended for single-use reconstitution.

The volume of bacteriostatic water you add sets the final concentration. A 5 mg vial reconstituted with 1 mL yields 5 mg per mL; the same vial with 2 mL yields 2.5 mg per mL. Both deliver the same total drug per vial, so the choice trades draw-volume convenience against syringe-rounding precision. Approved GLP-1 products do not offer this choice, because the manufacturer ships a fixed concentration.

What a defensible titration plan looks like, drawing from published trial design

STEP-1 tested once-weekly semaglutide 2.4 mg with a 16-week dose escalation before maintenance, and SURMOUNT-1 ran tirzepatide with a 20-week escalation period . Both climbed in four-week steps, and both reported the GI side effects (nausea, vomiting, constipation, diarrhea) landing mostly during the climb rather than at the top dose. SURMOUNT-1 says it plainly: most events were mild to moderate and occurred primarily during dose escalation . The four-week gap gives the gut time to adjust at each level and leaves room to catch a dose-related problem before the next jump.

Compress those four-week steps to two and you climb twice as fast, but the gut does not adapt twice as fast to match. Since the trial GI data clusters in the escalation window, running the escalation faster stacks the worst of the nausea and vomiting closer together, and early GI intolerance is a common reason people stop.

• Plan the whole ladder before the first injection, and pick the reconstitution concentration so every step lands in the 0.10 to 0.40 mL draw window.
• Write down the labeled-product dose at each step as a cross-check, and remember the approved GLP-1s are dosed once weekly, not monthly.
• Count weeks actually on each dose, not calendar weeks. A missed week does not advance the ladder.
• Set a stop-or-step-down rule up front for nausea or vomiting bad enough to threaten hydration. The label slows escalation for intolerance; a home plan usually has no such brake .

Where the dose calculator gets the answer right but misses the risk

• Vial-to-vial variance: compounded vials may not deliver the labeled mg per vial within tight tolerances, and concentrations vary between compounders and even within one compounder's stock . The calculator assumes the label is correct.
• Salt-form variability: some compounded preparations have used different salt forms (semaglutide sodium, semaglutide acetate), with different molecular weights and therefore different mg-equivalent doses for the same volume. The FDA has flagged these salt forms as different active ingredients from approved semaglutide, with equivalence not established .
• Storage decay: reconstituted peptide can lose potency over weeks in the fridge, especially if mishandled, while the calculator assumes the day-zero concentration holds forever. More on this in peptide storage and stability.
• Dead volume: insulin syringes are low-dead-space by design, which is one reason to use them. Reach for a standard syringe with a screw-on needle instead and the fluid left in the hub and needle becomes a real slice of a small draw.
• Reading variance: 0.005 mL looks different in different light and at different barrel angles. This is exactly the human error a factory-calibrated pen removes.

Missed doses and mid-titration interruptions

Wegovy's missed-dose rule: if a dose is missed and the next scheduled dose is more than 48 hours away, take the missed dose; if it is closer than that, skip it and resume on schedule. Miss two or more consecutive doses and you reinitiate escalation at a lower dose . Zepbound and Mounjaro: take a missed dose within 4 days (96 hours), otherwise skip and resume, and keep at least 3 days (72 hours) between any two doses .

For compounded product the same intervals apply, because pharmacokinetics is set by the molecule, not by who made it. The practical catch is that a longer gap resets your tolerance. Miss roughly two weeks and the sensible move is the one the label already spells out for its own product: restart escalation a step or two lower . Jump straight back to your old dose and the nausea and vomiting tend to come back with it.

What actually protects you: known inputs and a planned ladder

Compounded product is not FDA-verified, its concentration varies between vendors and even between one vendor's vials, and the salt-form question is unsettled . That is an argument for nailing the inputs, not for guessing. Confirm the mg per vial, measure the water you add, know the mg/mL you actually made, plan the full ladder, and let a calculator show the draw so the rounding is on screen.

The regulatory ground has also moved. The FDA declared the tirzepatide shortage resolved on October 2, 2024 and the semaglutide shortage resolved in February 2025, which closed the enforcement window that had allowed large-scale compounding of both . Sourcing is harder and less regulated than it was, which raises the stakes on getting the concentration and the ladder right yourself.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 8 entries, all primary canon (FDA alerts and drug labels via DailyMed plus two NEJM trials on PubMed), last reviewed 2026-07-08.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Dose-timing shifter overview - Public overview of the Pro timezone timing shifter.